News & Events

• January 28, 2014
  

  CFAST Launches Two New CDISC Therapeutic Area Standards

• July 10, 2013
  

  U.S. Food and Drug Administration and European Medicines Agency Reach Landmark Decisions on Critical Path Institute’s Clinical Trial Simulation Tool for Alzheimer’s Disease

• January 29, 2013
  

  CFAST Announces Parkinson’s Disease Drug Development Milestone: Release and Availability of a PD Therapeutic Area Data Standard

• January 23, 2012
  

  European Medicines Agency Deems Imaging Biomarker a Qualified Measure to Select Patients with Early Stages of Cognitive Impairment for Alzheimer’s Disease Clinical Trials

  Based on a request for regulatory review by Critical Path Institute’s (C-Path) Coalition Against Major Diseases (CAMD), the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has issued a positive opinion on the use of magnetic resonance imaging (MRI) to measure hippocampal volume as a tool to enrich recruitment into regulated clinical......
• June 11, 2010
  

  Public Release of Alzheimer’s Clinical Trial Data by Pharmaceutical Researchers